Research Article Details
| Article ID: | A26111 |
| PMID: | 21077292 |
| Source: | Rinsho Byori |
| Title: | [Chronic liver disease related to impaired glucose tolerance]. |
| Abstract: | Obesity has become a pandemic disease causing a variety of lifestyle-related diseases, such as hypertension, dyslipidemia, diabetes mellitus, liver cirrhosis and hepatocellular carcinoma; therefore obesity has become an important health issue all over the world. Obesity was suggested to cause a chronic liver disease called nonalcoholic steatohepatitis (NASH) and to promote the progression of NASH to liver cirrhosis and hepatocellular carcinoma 30 years ago and this was proven 20 years ago. Today, 1% of the Japanese population is suffering from NASH. Twenty percent of NASH patients, 0.2 million patients, are suggested to develop liver cirrhosis latently in the next decade, and are at a serious risk of developing hepatocellular carcinoma. Indeed, diabetes mellitus has become prevalent among the Japanese population and 10% die from chronic liver disease, but few doctors are able to recognize liver cirrhosis and hepatocellular carcinoma in patients with diabetes mellitus. It is a serious health issue to ignore such risk factors that threaten life in Japan. There are many chronic liver diseases with fatty liver, and nonalcoholic fatty liver disease (NAFLD), a chronic liver disease of unknown etiology, affects 14% of the Japanese population today. As NASH is the most progressive form of this disease, it has become a very important health issue to let doctors know how to recognize patients with NAFLD. In this paper, we discuss how to recognize NAFLD, including NASH, in our outpatient clinic. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I12 | 10763 | Hypertension | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |